Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus

por Heise, Tim, Donnelly, Charles, Barve, Abhijit, Aubonnet, Patrick
Publicado 2019

Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

por Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael
Publicado 2019

Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study

por Morgan, Christopher Ll, Owens, David R, Aubonnet, Patrick, Carr, Emma S M, Jenkins-Jones, Sara, Poole, Chris D, Currie, Craig J
Publicado 2013

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 s...

por Sun, Bin, Sengupta, Nilanjan, Rao, Anita, Donnelly, Charles, Waichale, Vinit, Roy, Arnab Sinha, Ramaswamy, Shilpa, Pathak, Divya, Bowsher, Ronald R., Raiter, Yaron, Aubonnet, Patrick, Barve, Abhijit
Publicado 2021